Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on September 14, 2005
Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005030226
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2005030226v1
16/11/3403    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vlagopoulos, P. T.
Right arrow Articles by Sarnak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vlagopoulos, P. T.
Right arrow Articles by Sarnak, M. J.

CLINICAL SCIENCE: Epidemiology and Outcomes

Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease

Panagiotis T. Vlagopoulos 1, Hocine Tighiouart 1, Daniel E. Weiner 1, John Griffith 1, Dan Pettitt 1, Deeb N. Salem 1, Andrew S. Levey 1, Mark J. Sarnak 1*

1

Divisions of *Nephrology, {dagger}Clinical Care Research, and ||Cardiology, Tufts-New England Medical Center, Boston, Massachusetts; and {sect}Pfizer Inc., New York, New York


* To whom correspondence should be addressed. E-mail: msarnak{at}tufts-nemc.org.


  Abstract

Anemia is a potential nontraditional risk factor for cardiovascular disease (CVD). This study evaluated whether anemia is a risk factor for adverse outcomes in people with diabetes and whether the risk is modified by the presence of chronic kidney disease (CKD). Persons with diabetes from four community-based studies were pooled: Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study, and Framingham Offspring Study. Anemia was defined as a hematocrit <36% in women and <39% in men. CKD was defined as an estimated GFR of 15 to 60 ml/min per 1.73 m2. Study outcomes included a composite of myocardial infarction (MI)/fatal coronary heart disease (CHD)/stroke/death and each outcome separately. Cox regression analysis was used to study the effect of anemia on the risk for outcomes after adjustment for potential confounders. The study population included 3015 individuals: 30.4% were black, 51.6% were women, 8.1% had anemia, and 13.8% had CKD. Median follow-up was 8.6 yr. There were 1215 composite events, 600 MI/fatal CHD outcomes, 300 strokes, and 857 deaths. In a model with a CKD-anemia interaction term, anemia was associated with the following hazard ratios (95% confidence intervals) in patients with CKD: 1.70 (1.24 to 2.34) for the composite outcome, 1.64 (1.03 to 2.61) for MI/fatal CHD, 1.81 (0.99 to 3.29) for stroke, and 1.88 (1.33 to 2.66) for all-cause mortality. Anemia was not a risk factor for any outcome in those without CKD (P > 0.2 for all outcomes). In persons with diabetes, anemia is primarily a risk factor for adverse outcomes in those who also have CKD.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, and G. Targher
Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2879 - 2883.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. M. Bertoli, L. M. Vila, M. Apte, B. J. Fessler, H. M. Bastian, J. D. Reveille, G. S. Alarcon, and for the LUMINA Study Group
Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual
Rheumatology, September 1, 2007; 46(9): 1471 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom
OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD)
Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. P.S. Kong, X. Yang, G. T.C. Ko, W.-Y. So, W.-B. Chan, R. C.W. Ma, V. W.S. Ng, C.-C. Chow, C. S. Cockram, P. C.Y. Tong, et al.
Effects of Treatment Targets on Subsequent Cardiovascular Events in Chinese Patients With Type 2 Diabetes
Diabetes Care, April 1, 2007; 30(4): 953 - 959.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. C.Y. Tong, A. P.S. Kong, W.-Y. So, M. H.L. Ng, X. Yang, M. C.Y. Ng, R. C.W. Ma, C.-S. Ho, C. W.K. Lam, C.-C. Chow, et al.
Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in chinese patients with type 2 diabetes.
Diabetes Care, November 1, 2006; 29(11): 2439 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. E. Imoagene-Oyedeji, S. E. Rosas, A. M. Doyle, S. Goral, and R. D. Bloom
Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3240 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. F. Culleton, B. J. Manns, J. Zhang, M. Tonelli, S. Klarenbach, and B. R. Hemmelgarn
Impact of anemia on hospitalization and mortality in older adults
Blood, May 15, 2006; 107(10): 3841 - 3846.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673